Fluoropyrimidine antimetabolite

This page covers all Fluoropyrimidine antimetabolite drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thymidylate synthase, Thymidylate synthase, dihydropyrimidine dehydrogenase.

Targets

Thymidylate synthase · Thymidylate synthase, dihydropyrimidine dehydrogenase

Marketed (4)

• Capecitabine (Xeloda®) · National Cancer Center, Korea · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
• Placebo plus S1 · Chinese PLA General Hospital · Oncology
  S1 is a combination chemotherapy agent that inhibits thymidylate synthase and dihydropyrimidine dehydrogenase to disrupt DNA synthesis and cell division.
• XELODA [capecitabine] · Hoffmann-La Roche · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
• Capecitabine tablets · UNICANCER · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.

Phase 3 pipeline (10)

• Placebo + Capecitabine · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
  Capecitabine is a prodrug that converts to fluorouracil in tumor tissue, inhibiting thymidylate synthase to disrupt DNA synthesis and induce cancer cell death.
• oral administration of S-1 · Japan Clinical Oncology Group · Oncology
  S-1 is an oral combination of tegafur, gimeracil, and oteracil that inhibits thymidylate synthase and fluorodeoxyuridylate synthase to block DNA synthesis in cancer cells.
• Capecitabine monotherapy · Zhen-Hai Lu · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
• LV5FU2 or capectitabine · Federation Francophone de Cancerologie Digestive · Oncology
  LV5FU2 and capecitabine are fluoropyrimidine chemotherapy agents that inhibit thymidylate synthase and get incorporated into DNA/RNA to disrupt cancer cell replication.
• Capecitabine-based chemotherapy · Ain Shams University · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell replication.
• TS-1 (S-1) · National Cancer Center, Korea · Oncology
  TS-1 (S-1) is an oral fluoropyrimidine combination that inhibits thymidylate synthase and other enzymes in the pyrimidine synthesis pathway to suppress tumor cell DNA synthesis.
• Capecitabine(Aibin) · The First Affiliated Hospital of Henan University of Science and Technology · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
• LV5FU2 or capecitabine · Federation Francophone de Cancerologie Digestive · Oncology
  LV5FU2/capecitabine is a fluoropyrimidine prodrug that inhibits thymidylate synthase and gets incorporated into DNA/RNA, disrupting cancer cell replication.
• Maintenance Therapy with Capecitabine · Jiangxi Provincial Cancer Hospital · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.
• UFT (uracil, tegafur) · Taiho Pharmaceutical Co., Ltd. · Oncology
  UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.

Phase 2 pipeline (1)

• Capecitabine Pill · Peter MacCallum Cancer Centre, Australia · Oncology
  Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.